Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Net Margin (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Net Margin for 4 consecutive years, with 70.13% as the latest value for Q1 2025.

  • Quarterly Net Margin rose 335224.0% to 70.13% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 8.83% through Dec 2025, up 1828.0% year-over-year, with the annual reading at 8.84% for FY2025, 1825.0% up from the prior year.
  • Net Margin for Q1 2025 was 70.13% at Century Therapeutics, down from 2125.76% in the prior quarter.
  • The five-year high for Net Margin was 2125.76% in Q4 2024, with the low at 33627.27% in Q2 2023.
  • Average Net Margin over 4 years is 7274.07%, with a median of 3545.65% recorded in 2022.
  • The sharpest move saw Net Margin crashed -3140750bps in 2023, then surged 2957967bps in 2024.
  • Over 4 years, Net Margin stood at 6080.04% in 2022, then tumbled by -142bps to 14700.75% in 2023, then skyrocketed by 114bps to 2125.76% in 2024, then plummeted by -97bps to 70.13% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 70.13%, 2125.76%, and 3947.66% for Q1 2025, Q4 2024, and Q3 2024 respectively.